Immunocore (IMCR)
(Delayed Data from NSDQ)
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Zacks News
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
by Zacks Equity Research
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
by Zacks Equity Research
Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
by Zacks Equity Research
Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
5 Biotech Stocks to Consider for Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
by Zacks Equity Research
Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
by Zacks Equity Research
REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
by Zacks Equity Research
Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Best Momentum Stocks to Buy for January 10th
by Zacks Equity Research
IMCR, CPRX and AMPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 10, 2024.
Should You Buy Immunocore Holdings PLC Sponsored ADR (IMCR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
New Strong Buy Stocks for January 10th
by Zacks Equity Research
PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.
Immunocore Holdings PLC Sponsored ADR (IMCR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 30.32%
by Zacks Equity Research
The consensus price target hints at a 30.3% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 75.55% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 75.6% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bears are Losing Control Over Immunocore Holdings PLC Sponsored ADR (IMCR), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts See a 66.42% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 66.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 60.86% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 60.9% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Earnings Season Could Be Great for Immunocore (IMCR)
by Zacks Equity Research
Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $48.54, marking a -1.74% move from the previous day.
Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $47.52, moving -0.71% from the previous trading session.
Immunocore Holdings PLC Sponsored ADR (IMCR) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Immunocore Holdings PLC Sponsored ADR (IMCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $46.71, moving -1.37% from the previous trading session.
Immunocore Holdings PLC Sponsored ADR (IMCR) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $53.51, moving +1.61% from the previous trading session.